Claims for Patent: 12,370,174

Summary for Patent: 12,370,174

Title:	Methods of improving renal function
Abstract:	Provided herein are methods of improving kidney function in a subject in need thereof.
Inventor(s):	Philip Thomas Frohlich, Andrew James KING, Chidambaram Ramachandran, Sarah Beth Noonberg
Assignee:	Chinook Therapeutics Inc
Application Number:	US18/990,351
Patent Claims:	1. A method of reducing proteinuria in a human subject having primary IgA nephropathy (IgAN), comprising administering to the subject from about 0.20 mg to about 1.5 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, thereby reducing proteinuria in the subject. 2. The method of claim 1, wherein the subject is administered about 0.75 mg of atrasentan or an equivalent amount of a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein atrasentan is administered as atrasentan hydrochloride. 4. The method of claim 2, wherein atrasentan is administered as atrasentan hydrochloride. 5. The method of claim 1, wherein atrasentan, or a pharmaceutically acceptable salt thereof, is administered as a tablet orally once daily. 6. The method of claim 2, wherein atrasentan, or a pharmaceutically acceptable salt thereof, is administered as a tablet orally once daily. 7. The method of claim 1, wherein the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, or acute kidney failure. 8. The method of claim 2, wherein the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, or acute kidney failure. 9. The method of claim 1, wherein the subject has proteinuria of at least about 1 g/day before administering atrasentan, or a pharmaceutically acceptable salt thereof. 10. The method of claim 2, wherein the subject has proteinuria of at least about 1 g/day before administering atrasentan, or a pharmaceutically acceptable salt thereof. 11. The method of claim 8, wherein the subject has proteinuria of at least about 1 g/day before administering atrasentan, or a pharmaceutically acceptable salt thereof. 12. The method of claim 1, wherein the subject has proteinuria of at least about 1.5 g/day before administering atrasentan, or a pharmaceutically acceptable salt thereof. 13. The method of claim 2, wherein the subject has proteinuria of at least about 1.5 g/day before administering atrasentan, or a pharmaceutically acceptable salt thereof. 14. The method of claim 1, wherein the subject has an estimated glomerular filtration rate (eGFR) of at least about 30 mL/min/1.73 m2 before administering atrasentan, or a pharmaceutically acceptable salt thereof. 15. The method of claim 2, wherein the subject has an eGFR of at least about 30 mL/min/1.73 m2 before administering atrasentan, or a pharmaceutically acceptable salt thereof. 16. The method of claim 1, wherein the subject has proteinuria of at least about 1 g/day and/or an eGFR of at least 30 mL/min/1.73 m2 before administering atrasentan, or a pharmaceutically acceptable salt thereof. 17. The method of claim 2, wherein the subject has proteinuria of at least about 1 g/day and/or an eGFR of at least 30 mL/min/1.73 m2 before administering atrasentan, or a pharmaceutically acceptable salt thereof. 18. The method of claim 1, wherein the subject's proteinuria level is reduced to below about 1.0 g/day after treatment with atrasentan, or a pharmaceutically acceptable salt thereof. 19. The method of claim 2, wherein the subject's proteinuria level is reduced to below about 1.0 g/day, or to below about 0.5 g/day, or to below about 0.3 g/day after treatment with atrasentan, or a pharmaceutically acceptable salt thereof. 20. The method of claim 1, wherein the subject's proteinuria is reduced by at least about 30% after treatment with atrasentan, or a pharmaceutically acceptable salt thereof. 21. The method of claim 2, wherein the subject's proteinuria is reduced by at least about 30% after treatment with atrasentan, or a pharmaceutically acceptable salt thereof. 22. The method of claim 10, wherein the subject's proteinuria is reduced by at least about 30% after treatment with atrasentan, or a pharmaceutically acceptable salt thereof. 23. The method of claim 21, wherein the subject's proteinuria is reduced by at least about 30% after 12 weeks of treatment, or by at least about 30% after 36 weeks of treatment with atrasentan, or a pharmaceutically acceptable salt thereof. 24. The method of claim 22, wherein the subject's proteinuria is reduced by at least about 30% after 12 weeks of treatment, or by at least about 30% after 36 weeks of treatment with atrasentan, or a pharmaceutically acceptable salt thereof. 25. The method of claim 1, wherein the subject has previously received or is concomitantly receiving a maximally tolerated stable dose of one or more renin-angiotensin system (RAS) inhibitors. 26. The method of claim 2, wherein the subject has previously received or is concomitantly receiving a maximally tolerated stable dose of one or more RAS inhibitors. 27. The method of claim 25, wherein the RAS inhibitor is an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker. 28. The method of claim 26, wherein the RAS inhibitor is an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker. 29. The method of claim 8, wherein the subject has proteinuria of at least about 2 g/day before administering atrasentan, or a pharmaceutically acceptable salt thereof. 30. The method of claim 29, wherein the subject's proteinuria is reduced by at least 30% after treatment with atrasentan, or a pharmaceutically acceptable salt thereof.